AntriaBio launches trial of once-weekly insulin

AntriaBio (OTC:ANTB) said today that the first patient was dosed in a Phase I first-in-human trial of its once-weekly basal insulin.

The single ascending dose study is designed to test the safety, pharmacokinetics and dynamics of AB101 in patients with Type I diabetes.

Get the full story at our sister site, Drug Delivery Business News.

The post AntriaBio launches trial of once-weekly insulin appeared first on MassDevice.

from MassDevice http://ift.tt/2h0xCQ1